arrow
G

Guruprasad R. Medigeshi

bric-translational health science and technology institute
H指数:32
被引数:3,131

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comorbidity-associated reduction in humoral and cellular immunity to respiratory syncytial virus in older adults at a tertiary care setting in India

在印度三级护理机构中,老年人群合并症相关的呼吸道合胞病毒体液和细胞免疫降低

2026-09-290
OAAI
Severe disease during both primary and secondary dengue virus infections in pediatric populations
2024-02-069
PRE
Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study
2024-01-290
OAAI
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
2023-04-2717
OAAI
Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth
2023-04-130
OAAI
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern
2022-12-1210
OAAI
Evaluation of safety and immunogenicity of receptor- binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
2022-09-0145
OAAI
Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India

印度德里国家首都地区新型冠状病毒肺炎确诊病例对SARS-CoV-2的抗体反应及其与中和试验的相关性

2022-08-142
OAAI
Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences
2022-05-0113
OAAI